Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · TAVEXIA LIFECARE LIMITED · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
TAVEXIA LIFECARE LIMITED
BSE: 539519
BSE: 539519
Consumer Discretionary › Consumer Services › Retailing › Distributors
TAVEXIA LIFECARE LIMITED
StateQ4 FY26 filed
Last close · 8 Oct 2026₹1.18
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA7.9 · 1.04 · 64.3
TAVEXIA LIFECARE LIMITED is a Retailing company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2 | 2 | 4 | 5 | 32 |
| EBITDA (ex other income) | 0 | 1 | 2 | 3 | (5) |
| margin % | 7.0 | 46.1 | 54.2 | 61.8 | (15.9) |
| Owners' profit | 0 | 0 | 1 | 2 | 0 |
| EPS, as reported (₹) | 0.03 | 0.37 | 0.48 | 0.13 | 0.01 |
| ROE % · ROCE % | 0.5 · 1.3 | 3.8 · 5.2 | 5.3 · 6.8 | 10.4 · 13.3 | 0.5 · 0.5 |
| Debt / equity (x) | 0.08 | 0.02 | 0.01 | 0.02 | 0.08 |
| Cash from operations | (1) | (1) | (2) | 1 | (14) |
| Capex | (0) | (1) | (0) | (0) | (3) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · TAVEXIA LIFECARE LIMITED · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 2 | 2 | 1 | 1 | 17 | 6 | 9 |
| Profit before tax | 0 | 1 | 1 | 1 | 1 | 1 | (1) | (1) |
| Net profit | 0 | 1 | 1 | 1 | 1 | 1 | (1) | (1) |
| EPS (₹) | 0.14 | 0.26 | 0.06 | 0.04 | 0.06 | 0.09 | (0.02) | 0.02 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| Khemani Distributors & Marketi | 261 | 5.7 | — | — | — | (21.7) | — | — |
| M K EXIM (INDIA) LTD. | 233 | 28.6 | 0.00 | — | 0.0 | 0.0 | — | 14.1 |
| ACE MEN ENGG WORKS LIMITED | 152 | 560.7 | 2.28 | 420.9 | 0.2 | 0.3 | — | 3.2 |
| MRP Agro Limited | 101 | 24.4 | — | — | — | 11.8 | — | — |
| TAVEXIA LIFECARE LIMITED ◆ | 45 | 7.9 | 1.04 | 64.8 | 0.5 | 0.4 | — | (8.0) |
| Kotia Enterprises Limited | 18 | — | 0.63 | — | (8.7) | (10.9) | — | (240.9) |
| Radhagobind Commercial Limited | 2 | — | — | — | 8.7 | 8.7 | — | — |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 7.9 | 23.7 | 13 of 52 | 77% |
| P/B | 1.0 | 2.8 | 17 of 50 | 67% |
| ROCE | 0.4 | 5.1 | 46 of 63 | 27% |
| ROE | 0.5 | 5.7 | 38 of 49 | 23% |
| Debt / Equity | 0.1 | 0.1 | 26 of 49 | 48% |
| EBITDA margin | (8.0) | 9.4 | 48 of 50 | 4% |
| Revenue growth | 708.5 | 16.2 | 1 of 51 | 100% |
| Profit growth | (184.3) | 26.5 | 45 of 46 | 2% |
| Market cap | 45 | 493 | 49 of 66 | 26% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · TAVEXIA LIFECARE LIMITED · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Oct 2026 · Board approves 60% acquisition of Meyonex Pharmaceuticals for Rs 67.19 crore | board shareholder meetings | low | — | — |
| 7 Oct 2026 · Tavexia Lifecare to acquire 60% in Meyonex Pharma for Rs 67.19 cr | board shareholder meetings | low | — | — |
| 1 Oct 2026 · 46th AGM: All 4 resolutions passed including Rs 100 Cr RPT approval | compliance | minimal | — | — |
| 30 Sept 2026 · 46th AGM held Sept 30, 2026 - 4 resolutions passed via e-voting | board shareholder meetings | low | — | — |
| 29 Sept 2026 · Board meeting on Oct 7 to discuss Meyonex Pharmaceuticals acquisition | board shareholder meetings | low | — | — |
| 29 Sept 2026 · Promoter group entity sells 2.5 lakh shares via on-market trade | ownership changes | high | — | — |
| 26 Sept 2026 · Trading window closed from 1 Oct 2026 for Q2 results | compliance | minimal | — | — |
| 26 Sept 2026 · Promoter group Roshan Dealmark sells 7 lakh shares on market | ownership changes | high | — | — |
| 25 Sept 2026 · Promoter entity Roshan Dealmark sells 2 lakh shares via open market | ownership changes | high | — | — |
| 24 Sept 2026 · Promoter group entity Roshan Dealmark sells 4 lakh shares via open market | ownership changes | high | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in